morphasol 4 mg/ml sol. inj. i.v. flac.
animedica-herstellungs gmbh - tartrate de butorphanol 5,83 mg/ml - eq. butorphanol 4 mg/ml - solution injectable - 4 mg/ml - tartrate de butorphanol 5.83 mg/ml - butorphanol - chien; chat
morphasol 10 mg/ml sol. inj. i.v. flac.
animedica-herstellungs gmbh - tartrate de butorphanol 14,7 mg/ml - eq. butorphanol 10 mg/ml - solution injectable - 10 mg/ml - tartrate de butorphanol 14.7 mg/ml - butorphanol - cheval
torbugesic vet 10 mg/ml sol. inj. i.m./i.v./s.c. flac.
zoetis belgium sa-nv - tartrate de butorphanol 14,58 mg/ml - eq. butorphanol 10 mg/ml - solution injectable - 10 mg/ml - tartrate de butorphanol 14.58 mg/ml - butorphanol - chien; cheval; chat
pentasa 4 g, granulés en sachet
ferring sas - mésalazine - granulés - 4 g - composition pour un sachet > mésalazine : 4 g - anti-inflammatoire intestinal
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
sarclisa
sanofi winthrop industrie - isatuximab - le myélome multiple - agents antinéoplasiques - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - des sérums et immunoglobulines, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - des sérums et immunoglobulines, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agents antinéoplasiques - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.